The antipsychotic market is worth an estimated $10.7 billion and is led by Eli Lilly’s blockbuster Zyprexa
December 4 2003--The antipsychotic market is worth an estimated $10.7 billion and is led by Eli Lilly’s blockbuster Zyprexa. After 2007, the market is expected to plateau due to the genericization of Janssen’s Risperdal and Pfizer’s Geodon. However, Bristol-Myers Squibb’s dopaminergic modulator Abilify, launched in 2002. has acheived good uptake and is predicted to reach blockbuster status by 2009.
Scope
Detailed coverage of the patient potential, unmet needs, and clinical trial design of antipsychotics across the seven major markets
Overview of drugs in preregistration, Phase III, II, I and preclinical development, with in-depth profiles of Organon and Sanofi-Synthelabo
Profiles of compounds undergoing development for schizophrenia, with sales forecasts to 2011
Insight into current research for novel diagnostic tests and the genetic basis of psychosis
Report Highlights
The current late stage antipsychotic pipeline is unlikely to yield a blockbuster product over the forecast period. Novartis has discontinued research of Zomaril with the drug now available for out-licensing, leaving Novartis’ antipsychotic pipeline empty.
Lundbeck’s Serdolect is set for relaunch in 2005, with post-marketing studies demonstrating that the drugs efficacy and safety profile is comparable to current frontline antipsychotics. However, Datamonitor is unsure whether this is enough to dispel the negative association with heart problems.
Novel neurotransmitter receptor ligands form the majority of drugs in Phase II and below. Due to the predicted high specificity and narrowed spectrum of efficacy, Datamonitor believes these compounds will be investigated as adjuncts, as a precursor to the predicted future of polytherapy.
This report is designed to:
Understand unmet needs in the antipsychotics market to identify new opportunities
Assess the commercial potential of new products entering the market
Identify in-licensing and co-promotional opportunities
For a complete index of this report click on http://www.researchandmarkets.com/reports/41466
About Research and Markets Ltd.
Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.
For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com
This article courtesy of http://www.zyprexa-side-effects.info.
You may freely reprint this article on your website or in
your newsletter provided this courtesy notice and the author
name and URL remain intact.